Publications by authors named "M Riek"
Recently, serious infections related to the use of tofacitinib (TOF) for treatment of rheumatoid arthritis (RA) have raised considerable interest. This study aimed to compare the risk for serious infections in patients with RA upon receiving TOF versus biologic disease-modifying antirheumatic drugs (bDMARDs) by age at treatment initiation. We identified adult RA patients exposed to TOF or bDMARDs using data collected by the Swiss registry for inflammatory rheumatic diseases (SCQM) from 2015 to 2018.
View Article and Find Full Text PDFArticle Synopsis
- Patients with inflammatory rheumatic diseases (IRD) are at greater risk of severe COVID-19 outcomes, prompting the need to evaluate the effectiveness of mRNA vaccines and treatments in this group.
- A study compared the antibody responses of IRD patients who received two doses of BNT162b2 and mRNA-1273 vaccines, analyzing samples at various intervals after vaccination.
- Results showed that mRNA-1273 led to significantly higher antibody levels compared to BNT162b2, particularly benefiting elderly patients, and specific medications lowered antibody responses.
In order to stabilize a 10-P-3 species with symmetry and two lone pairs on the central phosphorus atom, a specialized ligand is required. Using an NCN pincer, previous efforts to enforce this planarized geometry at P resulted in the formation of a -symmetric, 10π-electron benzazaphosphole that existed as a dynamic "bell-clapper" in solution. Here, OCO pincers 1 and 2 were synthesized, operating under the hypothesis that the more electron-withdrawing oxygen donors would better stabilize the 3-center, 4-electron O-P-O bond of the 10-P-3 target and the sp-hybridized benzylic carbon atoms would prevent the formation of aromatic P-heterocycles.
View Article and Find Full Text PDFObjectives: To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-modifying antirheumatic drugs (sDMARDs) in a large observational study.
Methods: Patients with rheumatoid arthritis treated with TCZ who had a baseline visit and information on concomitant sDMARDs were included. According to baseline data, patients were considered as taking TCZ as monotherapy or combination with sDMARDs.
Objectives: To determine the frequency of use of biologic DMARDs (bDMARDs) in monotherapy, to describe the baseline characteristics of patients treated with bDMARDs in monotherapy and to compare the effectiveness of bDMARDs in monotherapy with that of bDMARDs in combination with synthetic DMARDs (sDMARDs).
Methods: Using data from the Swiss RA (SCQM-RA) registry, bDMARD treatment courses (TCs) were classified either as monotherapy or as combination therapy, depending on the presence of concomitant sDMARDs. Prescription of bDMARD monotherapy was analysed using logistic regression.